• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

病例报告：左肾上腺意外发生的黏膜相关淋巴组织淋巴瘤，在不可切除的 III 期非小细胞肺癌的度伐利尤单抗维持治疗期间疑似转移扩散。

Case report: Incidental MALT lymphoma of the left adrenal gland mimicking a metastatic spread within durvalumab maintenance treatment in inoperable stage III non-small cell lung cancer.

作者信息

Käsmann Lukas, Degerli Esra, El-Marouk Karim, Manapov Farkhad

机构信息

Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.

German Center for Lung Research (DZL), Partner Site Munich, Munich, Germany.

出版信息

Front Oncol. 2024 Mar 19;14:1226422. doi: 10.3389/fonc.2024.1226422. eCollection 2024.

DOI:10.3389/fonc.2024.1226422
PMID:38567155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10985782/
Abstract

Durvalumab after chemotherapy in non-operable stage III non-small cell lung cancer (NSCLC) is the standard of care worldwide. We present a patient with the incidental discovery of a unilateral MALT lymphoma of the adrenal gland and adrenalitis during durvalumab maintenance treatment detected by 18F-FDG-PET/CT. We assessed the clinical and histopathological findings, radiological examinations and overall treatment. Our work emphasizes the significance of considering other differential diagnoses and the importance of multidisciplinary treatment of the findings, especially within clinical trials.

摘要

在不可切除的 III 期非小细胞肺癌（NSCLC）中，化疗后使用度伐鲁单抗是全球的治疗标准。我们报告了 1 例在度伐鲁单抗维持治疗期间经 18F-FDG-PET/CT 偶然发现肾上腺单侧黏膜相关淋巴组织淋巴瘤和肾上腺炎的患者。我们评估了临床和组织病理学检查结果、影像学检查及整体治疗情况。我们的工作强调了考虑其他鉴别诊断的重要性以及对这些检查结果进行多学科治疗的重要性，尤其是在临床试验中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/10985782/870c70feaae7/fonc-14-1226422-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/10985782/870c70feaae7/fonc-14-1226422-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/10985782/870c70feaae7/fonc-14-1226422-g001.jpg

相似文献

1
Case report: Incidental MALT lymphoma of the left adrenal gland mimicking a metastatic spread within durvalumab maintenance treatment in inoperable stage III non-small cell lung cancer.病例报告：左肾上腺意外发生的黏膜相关淋巴组织淋巴瘤，在不可切除的 III 期非小细胞肺癌的度伐利尤单抗维持治疗期间疑似转移扩散。
Front Oncol. 2024 Mar 19;14:1226422. doi: 10.3389/fonc.2024.1226422. eCollection 2024.
2
Metabolic patterns on [F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.不可切除 III 期 NSCLC 患者在放化疗 ± 度伐利尤单抗维持治疗中 [F]FDG PET/CT 的代谢模式。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2466-2476. doi: 10.1007/s00259-023-06192-6. Epub 2023 Mar 23.
3
18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report.18F-FDG PET/CT用于多部位受累的原发性腮腺黏膜相关淋巴组织淋巴瘤的分期及疗效评估：一例报告
Medicine (Baltimore). 2019 Feb;98(5):e14270. doi: 10.1097/MD.0000000000014270.
4
Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)-a German radiation oncology survey.同步放化疗后度伐鲁单抗维持治疗在不可切除的III期非小细胞肺癌（NSCLC）中的应用——一项德国放射肿瘤学调查
Transl Lung Cancer Res. 2020 Apr;9(2):288-293. doi: 10.21037/tlcr.2020.03.25.
5
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.度伐利尤单抗巩固治疗 III 期非小细胞肺癌的疗效：关注治疗选择和预后因素。
Immunotherapy. 2022 Aug;14(12):927-944. doi: 10.2217/imt-2021-0341. Epub 2022 Jul 13.
6
Durvalumab after concurrent chemoradiotherapy in a patient with chemotherapy-resistant unresectable stage III non-small cell lung cancer: a case report.同步放化疗后使用度伐鲁单抗治疗化疗耐药的不可切除Ⅲ期非小细胞肺癌患者：一例报告
Ann Palliat Med. 2020 Jul;9(4):2375-2380. doi: 10.21037/apm-20-1118. Epub 2020 Jul 20.
7
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.新辅助度伐利尤单抗联合化疗后序贯辅助度伐利尤单抗治疗可切除的II期和III期非小细胞肺癌患者的III期双盲安慰剂对照研究的设计与原理：爱琴试验
Clin Lung Cancer. 2022 May;23(3):e247-e251. doi: 10.1016/j.cllc.2021.09.010. Epub 2021 Oct 10.
8
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.度伐利尤单抗作为晚期非小细胞肺癌的三线或后线治疗药物（ATLANTIC）：一项开放标签、单臂、2 期研究。
Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.
9
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.PACIFIC 试验的探索性分析：放化疗后 durvalumab 治疗 IIIA-N2 期非小细胞肺癌的结果。
ESMO Open. 2022 Apr;7(2):100410. doi: 10.1016/j.esmoop.2022.100410. Epub 2022 Mar 2.
10
Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity.序贯高剂量放化疗后使用度伐利尤单抗对比III期非小细胞肺癌的标准治疗（SoC）：一项聚焦于肺部毒性的双中心回顾性比较
Cancers (Basel). 2022 Jun 30;14(13):3226. doi: 10.3390/cancers14133226.

本文引用的文献

1
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients.多学科建议基本基线功能和实验室检查，以促进癌症患者免疫相关不良事件的早期诊断和管理。
Cancer Immunol Immunother. 2023 Jul;72(7):1991-2001. doi: 10.1007/s00262-023-03436-0. Epub 2023 Apr 5.
2
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.度伐利尤单抗单药及联合治疗淋巴瘤或慢性淋巴细胞白血病患者：FUSION NHL 001 试验。
Cancer Rep (Hoboken). 2023 Jan;6(1):e1662. doi: 10.1002/cnr2.1662. Epub 2022 Jul 19.
3
Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment.
结外边缘区淋巴瘤：发病机制、诊断与治疗
Cancers (Basel). 2022 Mar 29;14(7):1742. doi: 10.3390/cancers14071742.
4
Role of F-FDG PET/CT in the differential diagnosis of primary benign and malignant unilateral adrenal tumors.F-FDG PET/CT在原发性单侧肾上腺良恶性肿瘤鉴别诊断中的作用
Quant Imaging Med Surg. 2021 May;11(5):2013-2018. doi: 10.21037/qims-20-875.
5
Clinical Features of 50 Patients With Primary Adrenal Lymphoma.50 例原发性肾上腺淋巴瘤患者的临床特征。
Front Endocrinol (Lausanne). 2020 Sep 24;11:595. doi: 10.3389/fendo.2020.00595. eCollection 2020.
6
FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.FDG PET/CT 用于评估免疫治疗：机遇与陷阱解析。
Semin Nucl Med. 2020 Nov;50(6):518-531. doi: 10.1053/j.semnuclmed.2020.06.001. Epub 2020 Jun 28.
7
Autoimmune complications of immunotherapy: pathophysiology and management.免疫治疗的自身免疫并发症：发病机制与管理。
BMJ. 2020 Apr 6;369:m736. doi: 10.1136/bmj.m736.
8
Non-adrenal tumors of the adrenal area; what are the pitfalls?肾上腺区非肾上腺肿瘤；有哪些陷阱？
J Visc Surg. 2020 Jun;157(3):217-230. doi: 10.1016/j.jviscsurg.2020.02.004. Epub 2020 Mar 20.
9
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的 5 年生存数据
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
10
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.免疫检查点抑制剂的不良反应：流行病学、管理和监测。
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0.